“Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s82, https://doi.org/10.25251/skin.4.supp.82.